Table 2.

Outcomes by baseline corticosteroid use irrespective of treatment group.

	Patients with baseline corticosteroid use n = 360 (30%)	Patients without baseline corticosteroid use n = 839 (70%)
Overall survival
Median (95% CI), months	10.8 (10.0–12.5)	NR (18.3–NR)
P value (stratified log-rank)	<0.0001
Stratified hazard ratio (95% CI)	2.13 (1.79–2.54)
Radiographic progression-free survival
Median (95% CI), months	5.2 (4.0–5.5)	8.0 (6.1–8.3)
P value (stratified log-rank)	<0.0001
Stratified hazard ratio (95% CI)	1.49 (1.29–1.72)
Time to PSA progression
Median (95% CI), months	4.6 (4.6–5.5)	5.7 (5.6–8,3)
P value (stratified log-rank)	<0.0001
Stratified hazard ratio (95% CI)	1.50 (1.25–1.81)

CI, confidence interval; NR, not reached; PSA, prostate-specific antigen.

Stratification factors are baseline Eastern Cooperative Oncology Group status (0 and 1 vs. 2) and baseline mean pain score (<4 vs. ≥4).

Hazard ratio is with corticosteroid use vs. without corticosteroid use.